Skip to main content
OpenTrials
Recruiting

NCT Number: NCT01246765

National Pregnancy Registry for Psychiatric Medications

The National Pregnancy Registry for Psychiatric Medications is dedicated to evaluating the safety of psychiatric medications such as antidepressants, ADHD medications, sedative hypnotics, and atypical antipsychotics that many people take during pregnancy to treat a wide range of mood, anxiety, executive function, or psychiatric disorders. The goal of this Registry is to gather information on the safety of these medications during pregnancy, as current data is limited.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–45 year

Sex eligibility

Female

Study type

Observational

Primary location

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location status: Recruiting

Location contact

Bryn Rediger, BA

CONTACT

[email protected]

(617) 724-8020

Lee Cohen, MD

PRINCIPAL_INVESTIGATOR

About this study

The overarching objectives of the National Pregnancy Registry for Psychiatric Medications are twofold: to assess risk for malformations among infants exposed to specific psychiatric medications and to assess neonatal outcomes associated with prenatal exposure to such medication. Specifically, the Registry will allow us to prospectively determine whether exposure to psychiatric medication is associated with any increased risk for major malformations above the baseline risk noted in the general population. This will be achieved by careful systematic documentation of medication exposure during pregnancy, as well as other relevant exposures often not included in small case series or published reviews of drug safety derived from large administrative databases.

Although psychiatric medications are widely used by reproductive age women, reliable data regarding the reproductive safety of many of these compounds is limited. As a result, clinicians often lack sufficient evidence to evaluate the risks and benefits of using medications to treat psychiatric disorders during pregnancy. The National Pregnancy Registry for Psychiatric Medications is one of the first, and largest, hospital-based pregnancy registries which will systematically and prospectively monitor pregnancy outcomes after exposure to psychiatric medications, including antidepressants, ADHD medications, sedative hypnotics, and atypical antipsychotics.

Primary Aim:

To prospectively evaluate rates of congenital malformations among infants exposed in-utero to psychiatric medications.

Secondary Aims:

  • To evaluate neonatal outcomes of infants with prenatal exposure to specific psychiatric medications alone or in combination with other psychotropics.
  • To evaluate maternal health outcomes associated with use of psychiatric medications during pregnancy.
  • To evaluate neurobehavioral development of children (1 month and older) with prenatal exposure to psychiatric medications.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pregnant women
  • Age 18-45
  • Subjects will be willing to participate over the phone
  • Subjects will be able to provide informed consent

Exclusion criteria

  • Women who have completed their pregnancy
  • Women who are planning to become pregnant
  • Women who are not taking any psychiatric medications and/or have no history of psychiatric illness

Treatment and study plan

Primary outcomes

  1. Major Malformations in Infants

    Time frame: Birth up to 1 year; assessed at 8-12 weeks postpartum, assessed through medical records through 1 year of age.

    The primary outcome for this study is rates of major malformations among infants exposed in-utero to psychiatric medications. A major malformation is defined as a structural abnormality with surgical, medical, or cosmetic importance. Exclusions include (1) minor anomalies; (2) deformations; (3) physiologic features due to prematurity, such as undescended testes; (4) birthmarks; (5) genetic disorders and chromosomal abnormalities; and (6) any finding by prenatal sonography, such as absence of 1 kidney, or at surgery (or autopsy) that was not identified by an examining pediatrician. This data is collected through review of pediatric medical records through the first twelve months of infants' lives.

Secondary outcomes

  1. Maternal Gestational Weight Gain

    Time frame: Change from pre-pregnancy to delivery; assessed at 7 months' gestation and 8-12 weeks postpartum.

    Maternal gestational weight gain is measured by the change in maternal weight from pre-pregnancy to weight at delivery, recorded in pounds.

  2. Live Birth

    Time frame: Birth; assessed at 8-12 weeks postpartum.

    Did the pregnancy end in a live birth, assessed as a yes/no outcome.

  3. Spontaneous Abortion (SAB)

    Time frame: Any time during pregnancy; assessed at 7 months' gestation and 8-12 weeks postpartum.

    Did a spontaneous abortion (SAB) occur during the pregnancy, assessed as a yes/no outcome.

  4. Intrauterine Fetal Demise (IUFD)

    Time frame: Any time during pregnancy; assessed at 7 months' gestation and 8-12 weeks postpartum.

    Did intrauterine fetal demise (IUFD) occur during the pregnancy, assessed as a yes/no outcome.

  5. Gestational Age

    Time frame: Birth; assessed at 8-12 weeks postpartum.

    The gestational age of the infant at birth, recorded in weeks and days.

  6. Preterm Delivery

    Time frame: Any time during pregnancy; assessed at 7 months' gestation and 8-12 weeks postpartum.

    Was the baby born before 37 weeks gestational age, assessed as a yes/no outcome.

  7. Birth Weight

    Time frame: Birth; assessed at 8-12 weeks postpartum.

    Birth weight of the infant, recorded in grams or lbs and oz

  8. Delivery Method

    Time frame: Birth; assessed at 8-12 weeks postpartum.

    Was birth vaginal or by C-section; if C-section, emergent: yes/no

  9. Gestational Diabetes

    Time frame: Any time during pregnancy; assessed at baseline, 7 months' gestation and 8-12 weeks postpartum.

    Gestational diabetes diagnosed during pregnancy, assessed as a yes/no outcome.

  10. Gestational Hypertension

    Time frame: Any time during pregnancy; assessed at baseline, 7 months' gestation and 8-12 weeks postpartum.

    Gestational hypertension diagnosed during pregnancy, assessed as a yes/no outcome.

  11. Preeclampsia/Eclampsia

    Time frame: Any time during pregnancy; assessed at baseline, 7 months' gestation and 8-12 weeks postpartum.

    Pre-eclampsia or eclampsia diagnosed during pregnancy, assessed as a yes/no outcome.

  12. Maternal Postpartum Hemorrhage

    Time frame: Birth; assessed at 8-12 weeks postpartum.

    Did maternal postpartum hemorrhage occur, assessed as a yes/no outcome.

  13. Apgar Scores

    Time frame: Birth; assessed at 8-12 weeks postpartum.

    1-min and 5-min Apgar scores.

  14. Neonatal Intensive Care Unit (NICU) admission

    Time frame: Birth up to 1 year; assessed at 8-12 weeks postpartum, assessed through medical records through 1 year of age.

    Was the infant admitted to the NICU, assessed as a yes/no outcome; if yes, number of days in NICU and reason for admission

  15. Infant Death

    Time frame: Birth up to 1 year; assessed at 8-12 weeks postpartum, assessed through medical records through 1 year of age.

    Did the infant die before the age of one; assessed as a yes/no outcome.

  16. Neonatal Extrapyramidal Symptoms

    Time frame: Birth through 1 year; assessed at 8-12 weeks postpartum, assessed through medical records through 1 year of age.

    Did movement dysfunction occur in the infant (such as dystonia, akathisia, parkinsonism characteristic symptoms such as rigidity, bradykinesia, tremor, and tardive dyskinesia); assessed as a yes/no outcome.

  17. Poor Neonatal Adaptation Syndrome (PNAS)

    Time frame: Birth through 1 year; assessed at 8-12 weeks postpartum, assessed through medical records through 1 year of age.

    Did poor neonatal adaptation syndrome (PNAS) occur (including poor muscle tone, tremors, jitteriness, irritability, seizures, feeding difficulties, sleep disturbances, hypoglycemia, and respiratory distress); assessed as a yes/no outcome

  18. Child Development Outcomes - Ages and Stages Questionnaire (ASQ-3)

    Time frame: Assessed at 9 months, year 3, and year 5.

    Were there developmental concerns, as assessed by the Ages and Stages Questionnaire (ASQ-3).

  19. Child Development Outcomes - Preschool Child Behavior Checklist (CBCL)

    Time frame: Assessed at 9 months, year 3, and year 5.

    Were there developmental concerns, as assessed by the Preschool Child Behavior Checklist (CBCL).

  20. Breastfeeding

    Time frame: Assessed at 8-12 weeks postpartum.

    Did breastfeeding occur, assessed as a yes/no outcome; if yes, duration of breastfeeding recorded in weeks.

Study contacts

Contact information is provided by the study sponsor or research team.

Bryn Rediger

CONTACT

[email protected]

(617) 724-8020

Lee Cohen, MD

CONTACT

[email protected]

(617) 724-8020

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Collaborators

  • Alkermes, Inc.
  • Bristol-Myers Squibb
  • Eisai Inc.
  • Otsuka America Pharmaceutical
  • Sage Therapeutics
  • Supernus Pharmaceuticals, Inc.

Registry information

Important dates

Study start
2008
Primary completion
2033
Study completion
2033
First posted
Nov 23, 2010
Registry last updated
Oct 24, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.